Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ANI Pharmaceuticals

ANI Pharmaceuticals
PUBLIC STATUS
201-300 EMPLOYEES
ANIP STOCK SYMBOL
18 INVESTMENTS
$55.74 SHARE PRICE (As of Friday Closing)
Description

ANI Pharmaceuticals Inc develops, manufactures and markets generic prescription pharmaceuticals, made in the U.S.A. It manufactures liquid, powder and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Its generic products include Erythromycin Ethylsuccinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Flecainide, Fluvoxamine, Hydrocortisone Enema, Methazolamide, Metoclopramide Syrup Nilutamide, Nimodipine, Opium Tincture, Oxycodone Capsules, Oxycodone Oral Solution, Propafenone, and Vancomycin.

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Other Healthcare Services
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 210 Main Street West
  • Baudette, MN 56623
  • United States

+1 (218) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore ANI Pharmaceuticals’s full profile, request a free trial.

ANI Pharmaceuticals Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$36.92 - $86.96 $674M $55.65 $1.37 195K 12.1M

ANI Pharmaceuticals Financials Summary

In Thousands,
USD
TTM
30-Sep-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 1,026,745 695,461 884,347 805,315
Revenue 215,703 201,576 176,842 128,622
EBITDA 75,605 68,551 56,312 42,348
Net Income 16,359 15,494 (1,076) 3,934
Total Assets 456,775 430,604 412,138 322,864
Total Debt 186,613 183,015 201,507 120,643
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ANI Pharmaceuticals Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore ANI Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

ANI Pharmaceuticals Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Lannett Company Formerly PE-Backed Philadelphia, PA 0000 00000 000000000 00000
0000000 00000 Private Equity-Backed Pine Brook, NJ 0000 00000 000000000 00000
000000 00000000000 Formerly PE-Backed Bridgewater, NJ 0000 00.000 000000 - 000 00.000
0000000 0000000000 Corporate Backed or Acquired Hauppauge, NY 000 000000&0
00000000 000000000 Private Equity-Backed Stockholm, Sweden 000 000.00 000000 - 000 000.00
To view this company’s complete list of competitors, request access »

ANI Pharmaceuticals Investments & Acquisitions (18)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 000000 06-Aug-2018 000000000000000000 0000 Other Pharmaceuticals and Biotechnology 000000 0000000
000000 000 00000 ( 07-May-2018 000000000 00000 00 Buildings and Property 000000 0000000
00000 000000000000 07-May-2018 000000000 00000 00 00.00 Drug Delivery 000000 0000000
000 000000000 (00 04-Apr-2018 000000000 00000 00 00.000 Buildings and Property 000000 0000000
AstraZeneca (NDAs and U.S. Rights to 4 Pharmaceutical Products) 29-Dec-2017 Corporate Asset Purchase 000.00 Other Commercial Services 000000 0000000
To view this company’s complete investment and acquisition history, request access »

ANI Pharmaceuticals Subsidiaries (1)

Company Name Industry Location Founded
0000000000 000000 Other Pharmaceuticals and Biotechnology Oakville, Canada 0000
To view this company’s complete subsidiary history, request access »

ANI Pharmaceuticals Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore ANI Pharmaceuticals‘s full profile, request access.

Request full access to PitchBook

ANI Pharmaceuticals Executive Team (9)

Name Title Board
Seat
Contact
Info
Arthur Przybyl Chief Executive Officer & Board Member
Stephen Carey Chief Financial Officer & Vice President
Robert Schrepfer Senior Vice President
James Marken Vice President

5 Former Executives

You’re viewing 4 of 9 executives. Get the full list »

ANI Pharmaceuticals Board Members (1)

Name Representing Role Since Contact
Info
000000 0000000 ANI Pharmaceuticals Chief Executive Officer & Board Member 000 0000